Evidence mapPaperPMID 42544244Full record

ReviewInternational journal of nanomedicine2026

Theranostic Nanoprobes for Rheumatoid Arthritis: From Inflammation Visualization to Guided Precision Therapy.

Manting Hao, Yufei Zhu, Zhuoyi Su, Xing Liu

Abstract readReview
In one paragraph

Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Manting HaoThe First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, 510000, People's Republic of China.ORCID 0009-0000-7566-8900
Yufei ZhuThe Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai, 519000, People's Republic of China.ORCID 0009-0004-3110-8038
Zhuoyi SuThe First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, 510000, People's Republic of China.ORCID 0009-0008-2379-7100
Xing LiuThe First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, 510000, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent synovitis, progressive joint damage, and considerable heterogeneity in disease evolution and treatment response. The concept of theranostic nanoprobes has recently moved beyond multifunctional carriers that simply package imaging and therapeutic agents; instead, these platforms are being designed to establish an integrated imaging-therapy-feedback loop that enables disease-specific targeting, real-time molecular visualization, on-demand intervention, and dynamic monitoring of treatment effects-all within a single system. This review traces the evolution of RA theranostic nanoprobes along this trajectory, from molecular targeting and inflammation imaging, through therapeutic delivery and response monitoring, toward adaptive precision management. We first outline the pathological and biological features that enable selective homing to inflamed joints and subsequent molecular imaging of disease activity. We then survey current therapeutic strategies-including anti-inflammatory drug delivery, immunomodulation, redox regulation, and phototherapy-with an emphasis on how these modalities are being functionally coupled with imaging capabilities to support image-guided intervention and treatment feedback. Building on these advances, we propose a conceptual framework that distinguishes fully integrated theranostic platforms from conventional diagnostic nanoprobes and therapeutic nanocarriers. While preclinical progress has been substantial, clinical translation remains hindered by outstanding challenges in long-term safety, biodistribution, repeat-dose compatibility, manufacturing reproducibility, regulatory complexity, and validation against established clinical endpoints. Future advances will require not only improved nanoparticle design but also standardized translational evaluation and closer integration with clinically relevant disease-assessment strategies.

Indexed as

Arthritis, RheumatoidNanoparticlesPrecision MedicineTheranostic NanomedicineAnimalsAnti-Inflammatory AgentsDrug Delivery SystemsHumansInflammationMolecular ImagingPhototherapyAnti-Inflammatory Agentsclinical translationdrug delivery systemsimaging-guided therapymolecular imagingpathological targeting

Identifiers

PMID42544244
PMCPMC13429120

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.